Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Drug Alcohol Depend. 2018 Mar 10;186:130–137. doi: 10.1016/j.drugalcdep.2018.01.017

Table 3.

a. Proportions of days ATS abstinent
Means (95% CI)
Intention-to-treat
sample		 Baseline Weeks 1–8 Weeks 9–16 P values
Placebo (n=32) 0.37 (0.24–0.49) 0.91 (0.85–0.98) 0.90 (0.82–0.97)

  • Medication: p=0.42

  • Time: p<0.001

  • Med x Time interaction: p=0.63
Atomoxetine (n=33) 0.44 (0.32–0.56) 0.90 (0.84–0.97) 0.92 (0.84–1.00)
Means (95% CI) Higher adherence subsample Baseline Weeks 1–8 Weeks 9–16 P values
Placebo (n=16) 0.38 (0.20–0.55) 0.88 (0.79–0.98) 0.87 (0.78–0.96)

  • Medication: p=0.14

  • Time: p<0.001

  • Med x Time interaction: p=0.89
Atomoxetine (n=12) 0.42 (0.22–0.63) 0.97 (0.86–1.00) 0.98 (0.88–1.00)
b. Proportions of days opioid abstinent
Means (95% CI)
Intention-to-treat
sample		 Baseline Weeks 1–8 Weeks 9–16 P values
Placebo (n=32) 0.02 (0.00–0.07) 0.92 (0.84–0.99) 0.91 (0.83–0.98)

  • Medication: p=0.60

  • Time: p<0.001

  • Med x Time interaction: p=0.94
Atomoxetine (n=33) 0.02 (0.00–0.04) 0.85 (0.77–0.92) 0.83 (0.75–0.91)
Means (95% CI) Higher adherence subsample Baseline Weeks 1–8 Weeks 9–16 P values
Placebo (n=16) 0.04 (0.00–0.13) 0.92 (0.83–1.00) 0.91 (0.86–0.97)

  • Medication: p=0.96

  • Time: p<0.001

  • Med x Time interaction: p=0.66
Atomoxetine (n=12) 0.00 (0.00–0.00) 0.90 (0.80–1.00) 0.93 (0.86–1.00)